ClinicalTrialsFinder

Leukapheresis Clinical Trials

36 recruitingProcedure
Phase 122Phase 210Early Phase 14Phase 32

Showing 1–20 of 36 trials

Recruiting
Phase 1Phase 2

ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma

Recurrent Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell LymphomaRecurrent High Grade B-Cell Lymphoma+9 more
Fred Hutchinson Cancer Center33 enrolled1 locationNCT07098364
Recruiting
Phase 3

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

NeuroblastomaGanglioneuroblastoma, Nodular
National Cancer Institute (NCI)478 enrolled178 locationsNCT06172296
Recruiting
Phase 3

Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedAnaplastic Large Cell Lymphoma, ALK-negativeFollicular Helper T-Cell Lymphoma+1 more
Eastern Cooperative Oncology Group294 enrolled158 locationsNCT06724237
Recruiting
Phase 1

Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations

Metastatic Malignant Solid Neoplasm
Fred Hutchinson Cancer Center24 enrolled1 locationNCT06043713
Recruiting
Phase 2

Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma

Large B-cell Lymphoma
M.D. Anderson Cancer Center50 enrolled1 locationNCT07316010
Recruiting
Phase 1

Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma

Recurrent Astrocytoma, IDH-Mutant, Grade 3Recurrent Astrocytoma, IDH-Mutant, Grade 4Recurrent Glioblastoma
City of Hope Medical Center27 enrolled1 locationNCT06815029
Recruiting
Phase 1Phase 2

Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

Stage IVB Prostate Cancer AJCC v8Metastatic Prostate AdenocarcinomaMetastatic Castration-Resistant Prostate Carcinoma
Fred Hutchinson Cancer Center48 enrolled1 locationNCT06236139
Recruiting
Early Phase 1

N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy

Synovial SarcomaMyxoid LiposarcomaRound Cell Liposarcoma
Seth Pollack8 enrolled1 locationNCT07261657
Recruiting
Phase 1

Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas

Recurrent Astrocytoma, IDH-Mutant, Grade 4Recurrent Glioblastoma, IDH-Wildtype
City of Hope Medical Center24 enrolled1 locationNCT07544992
Recruiting
Phase 1

Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
Roswell Park Cancer Institute26 enrolled1 locationNCT06871410
Recruiting
Phase 1

Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/Mem T-lymphocytes) for the Treatment of Central Nervous System Lymphoma

Central Nervous System Lymphoma
City of Hope Medical Center20 enrolled1 locationNCT05625594
Recruiting
Phase 1

Study of CD19 Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia

Pediatric ALLAcute Lymphoblastic Leukemia, in RelapseAcute Lymphoblastic Leukemia Refractory
St. Jude Children's Research Hospital60 enrolled1 locationNCT04881240
Recruiting
Phase 1

CARPALL: Immunotherapy With CD19+CD22 CAR T-cells for CD19+ and CD22+ Acute Lymphoblastic Leukaemia

Acute Lymphoblastic Leukemia
University College, London50 enrolled3 locationsNCT02443831
Recruiting
Phase 1

A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer

Triple-Negative Breast Cancer
University of Southern California20 enrolled1 locationNCT05989828
Recruiting
Phase 1

A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas

LymphomasB-cell Lymphomas
M.D. Anderson Cancer Center33 enrolled1 locationNCT05773040
Recruiting
Phase 2

Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T

Recurrent Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell LymphomaRecurrent High Grade B-Cell Lymphoma+9 more
University of Washington27 enrolled1 locationNCT06784726
Recruiting

The Use of Leukapheresis to Support HIV Pathogenesis Studies

HIV
University of California, San Francisco100 enrolled1 locationNCT01161199
Recruiting
Early Phase 1

Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia
City of Hope Medical Center15 enrolled1 locationNCT06735690
Recruiting
Phase 1

177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Stage IVB Prostate Cancer AJCC v8Metastatic Castration-Resistant Prostate Adenocarcinoma
City of Hope Medical Center30 enrolled1 locationNCT07219147
Recruiting
Phase 1

CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma

Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
City of Hope Medical Center30 enrolled1 locationNCT03710421